Get the Stockscreener App
10.63
0.09%
0.01
After Hours:
10.62
-0.01
-0.09%
Drugs Made In America Acquisition Corp stock is traded at $10.63, with a volume of 14,773.
It is up +0.09% in the last 24 hours and up +0.28% over the past month.
Drugs Made In America Acquisition Corp is a blank check company.
See More
Previous Close:
$10.62
Open:
$10.63
24h Volume:
14,773
Relative Volume:
0.11
Market Cap:
$258.06M
Revenue:
-
Net Income/Loss:
$6.66M
P/E Ratio:
53.63
EPS:
0.1982
Net Cash Flow:
$-379.20K
1W Performance:
+0.19%
1M Performance:
+0.28%
6M Performance:
+2.61%
1Y Performance:
+4.32%
1-Day Range:
$10.62
$10.63
1-Week Range:
$10.61
$10.63
52-Week Range:
$10.17
$10.63
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Name
Drugs Made In America Acquisition Corp
Sector
Industry
Phone
646-726-7074
Address
420 LEXINGTON AVENUE, NEW YORK
Compare DMAA vs LION, XXI, UMAC, DMII, BCSS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.63 | 257.82M | 0 | 6.66M | -379.20K | 0.1982 |
LION
Lionsgate Studios Corp
|
15.49 | 4.46B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
5.52 | 1.96B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
24.98 | 1.17B | 17.25M | -5.64M | -40.16M | -0.3337 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.10 | 643.37M | 0 | 8.58M | -1.11M | 0.134 |
BCSS
Bain Capital Gss Investment Corp
|
10.21 | 596.26M | 0 | 8.29M | -686.50K | 0.142 |
Drugs Made In America Acquisition Corp Stock (DMAA) Latest News
Drugs Made In America Acquisition Corp (DMAAR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Institutional Confidence - TradingKey
Drugs Made In America Acquisition Corp (DMAA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Drugs Made In America Acquisition Corp (DMAA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 (DMIIR) Institutional Confidence - TradingKey
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 (DMIIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Drugs Made In America Acquisition II Ord Shs (DMII) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Drugs Made In America Acquisition Corp (DMAA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Drugs Made In America Acquisition II Units - TradingKey
Drugs Made In America Acquisition II Units (DMIIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Drugs Made In America Acquisition II Ord Shs (DMII) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Drugs Made In America Acquisition II Ord Shs (DMII) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Drugs Made In America Acquisition Corp - TradingKey
Drugs Made In America Acquisition Corp (DMAAU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Drugs Made In America Acquisition Corp (DMAAR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DMAA Holds Near $10.62 as Support and Resistance Levels TightenDouble Top - newsline.com
DMAAR Rights Trade Flat Near All-Time Low as Investors Await Merger CatalystBearish Pattern Stocks - newsline.com
DMAA Hovers Near $10.62 as SPAC Consolidates Ahead of Potential CatalystFair Value Gap - newsline.com
US Retreat from Global Leadership Stirs Uncertainty Across AsiaFinancial Health Score - newsline.com
DMAAR Rights Hold Steady at $0.10: Analyzing the Stalemate for Drugs Made In America Acquisition Corp.Channel Breakout - newsline.com
Drugs Made In America Acquisition II Corp. Right (DMIIR) Holds Flat at $0.08 as Rights Trading Remains DormantDip Buy Trade - newsline.com
DMII Holds Steady at $10.08: SPAC Trading in a Narrow RangeTICK Divergence - newsline.com
DMIIU Holds Steady at $10.12 as SPAC Unit Trades in Tight RangeFear Greed Extreme - newsline.com
DMIIR Rights Trading Slumps 9.09% to $0.08 – Micro-Cap Struggles for DirectionReversal Setup Alerts - newsline.com
SUNE Q2 2024 Earnings: EPS Surges Past Estimates Despite Heavy Losses; Stock Plummets 27%Fiscal Year Earnings - newsline.com
Grove Collaborative (GROV) Edges Higher as Shares Approach Resistance ZoneSMA Signal - newsline.com
Number of shareholders of Drugs Made In America Acquisition II Corp. – NASDAQ:DMIIR - TradingView
GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover - Reuters
Free float of Drugs Made In America Acquisition II Corp. – NASDAQ:DMIIR - TradingView
Brand Engagement Network Inc. (BNAI) Q3 2025 Earnings: Narrowed Loss Surprises as Pre-Revenue Company Gains MomentumEarnings Growth Forecast - newsline.com
Broadcom, Micron, ARM Lead Chip Stock Decline After Disappointing Broadcom EarningsHigh Estimate Range - newsline.com
Free float of Drugs Made In America Acquisition Corp. – NASDAQ:DMAAR - TradingView
QDRO Acquisition Corp.: Performance & Quotes, QADR Stock Price on Nasdaq Exchange - marketscreener.com
Drugs Made In America Acquisition II Corp. appoints new CEO after sponsor repayment issue - Investing.com
Drugs Made In America Acquisition Corp. Rights (DMAAR) Edge Higher Amid Low-Price SpeculationSector Leader Stocks - newsline.com
DeFi Development Corp. Warrant (DFDVW) Testing Support After 3.85% DeclineRatio Spread Trade - thelegaladvocate.com
VTAK Q1 2025 Earnings: Significant EPS Miss Amid Operational ChallengesEarnings Call Transcript - newsline.com
Shalibhadra Finance Targets Rs 500 Crore AUM on 22% Profit Growth in FY26Net Income Trends - thelegaladvocate.com
SQM Q2 2025 Earnings: Lithium Miner Posts $0.31 EPS as Shares Rise 2.17% Amid Market UncertaintyEarnings Weakness Phase - lwvtexas.org
Drugs Made In America Acquisition II Corp. Right (DMIIR) Drops 10% as Rights Trade Near Support at $0.08Volatility Breakout Picks - The Legal Advocate
Drugs Made In America Acquisition II Corp. Unit (DMIIU) Holds Steady Amid Extended ConsolidationVolatility Smirk - The Legal Advocate
Drugs Made In America Acquisition Corp. Rights (DMAAR) Slides 7.4% – Testing Key Support ZoneRip Sell Trade - newsline.com
NXRT Q1 2026 Earnings: Narrower-Than-Expected Loss, Stock Edges LowerBanking Earnings Report - thelegaladvocate.com
Drugs Made In America Acquisition II Corp. Right (DMIIR) Moves Up 8.91% at $0.09 – Right Securities See Renewed InterestGamma Squeeze - The Legal Advocate
Harvard Ave Acquisition (HAVA) Stock Holds Steady at $10.08 as Trading Remains FlatZero Lag EMA - The Legal Advocate
NXGL Q1 2026 Earnings: Larger-Than-Expected Loss Weighs on SharesEarnings Manipulation Risk - thelegaladvocate.com
Drugs Made In America Acquisition Corp Stock (DMAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):